Basic science for the clinician 31: CD molecules of relevance to immunity, inflammation, and rheumatologic syndromes.
Molecular biologic technology has allowed us to study some of the many proteins expressed by leukocytes at different stages of differentiation, activation, and proliferation. Being able to purify cells with 1 or more surface molecules (eg, by FACS or lysis) with monoclonal antibodies and complement and identifying changes as cells are stimulated or activated has given us real insights into what is happening and how we might be able to modify cells that are going astray (eg, malignancy, autoimmunity). Over the years, there has been remarkable cooperation between laboratories to bring order out of chaos; by trading reagents, scientists have been able to identify the molecules being identified by different laboratories and come up with standardized names, often within the CD, or "clusters of differentiation," framework. These names are not acronyms, and the function and role of the molecule bearing a certain CD designation is not apparent. Worse, the proliferation of numbered CD molecules (over 250, with more to come after another conference in 2004) makes interpretation of the literature very difficult for those not immersed in the field. Thus, I have chosen (nearly arbitrarily and often based on my own interests) a number of CD molecules to briefly describe, pointing out the clinical relevance of each. It is worth reflecting on the fact that many of these were discussed in previous contributions to this series (as is pointed out in the following article). For those of you with the fortitude to follow this series, see how far you (and all of science) have come!
Sigal
Leonard H
LH
Pharmaceutical Research Institute-Bristol-Myers Squibb, Princeton, New Jersey 08543-4000, USA. leonard.sigal@bms.com